Why eTMF validation must now prove record integrity under ICH E6(R3).
Audit-trail review as a planned, documented activity under ICH E6(R3) exposes a problem many sponsors have tried to treat as an IT formality: if your eTMF system is not demonstrably fit for purpose, your inspection-readiness story weakens fast. Section 4.3 of ICH E6(R3) makes computerized systems validation a direct record-integrity issue, not a background implementation detail.
For Regulatory Affairs leads, Clinical Operations Directors, Quality heads, and validation owners, that matters because the eTMF is no longer just a storage layer. Under Appendix C, essential records now include documents, metadata, and data that support ongoing trial management and reconstruction of conduct. If the system controlling those records cannot prove reliable version history, role-based access, traceable metadata change, interpretable audit trails, and durable retrieval, then the sponsor has a system problem that becomes a quality problem under inspection.
Many organizations still approach validation as if a release package settles the question. User requirements are approved, scripts are executed, deviations are closed, and the system is considered validated. But under R3, the more useful question is whether the system remains fit for purpose as trial workflows evolve. A validated upload function is not enough if the metadata rules around country and site context drift. A validated approval workflow is not enough if teams compensate for operational gaps with spreadsheets and side channels. A validated repository is not enough if essential records become hard to retrieve in the context regulators actually ask about.
This is why computerized system validation is becoming a live operating concern for eTMF programs. The eTMF has to preserve not only the document, but the integrity of the record around that document across its lifecycle. That includes metadata, user actions, permissions, version changes, and connections to trial events. It is also why the Cloudbyz position is straightforward: sponsors should stop thinking about validation as a bind-and-file exercise and start treating it as evidence that the platform can support continuous inspection readiness in live trial conditions.
The structural problem is that many validation programs still behave like document packages rather than operating controls. They prove that a system was tested at release, but they do not reliably prove that the system remains fit for purpose as trial workflows evolve, integrations change, and users stretch processes under real pressure. That gap is dangerous under ICH E6(R3) because record integrity is now tied directly to data governance, metadata review, audit-trail review, and the ongoing accessibility of essential records.
Section 4.3 of ICH E6(R3) is clear that computerized systems used in clinical trials must be fit for purpose, with risk-based validation, security, user management, backup, and change control addressed proportionately to the importance of the system and the data it handles. For eTMF, that means validation cannot stop at upload, retrieval, and signature workflows. Sponsors have to think about how the system preserves version history, how metadata is controlled, how audit trails remain interpretable, how user roles reflect blinding and segregation needs, and how integrations affect traceability between CTMS events and TMF records.
That is where static validation evidence begins to fail. A completed IQ/OQ/PQ set may satisfy an audit binder, yet still leave critical questions unanswered in live operations. What happens when a protocol amendment introduces a new document flow? What happens when a CRO uploads records through a separate operational path? What happens when a metadata rule changes mid-study, or when a team begins depending on dashboards and alerts that were not central to the original validation narrative? In many environments, the answer is procedural workarounds, local trackers, or manual reviews that sit outside the platform’s strongest controls.
Under Section 4.2.3, review of trial-specific data and metadata, including audit trails, should be planned, risk-based, and documented. That requirement effectively turns validation into a living discipline. If a system supports essential records, then the sponsor needs ongoing confidence that the workflows producing and managing those records are still behaving as intended. Otherwise, validation becomes historical proof about a system that no longer quite matches the way the trial is actually run.
Cloudbyz’s answer is to make validation easier to defend because the operating model is unified from the start. Cloudbyz is the only 100% Salesforce-native unified eClinical platform, which means CTMS and eTMF share the same core data, security, workflow, and audit foundations rather than being stitched together across disconnected stacks. That directly reduces one of the most common sources of validation strain: proving integrity across system boundaries.
In the Cloudbyz model, native CTMS to eTMF connection on Salesforce means milestones, documents, and site activities reconcile automatically. That matters for validation because key workflows do not have to rely on brittle handoffs, duplicated states, or external reconciliation logic. The evidence trail for a milestone-linked document process can be examined within one governed operating environment. For Clinical Operations, Regulatory, Quality, and IT validation leaders, that is a practical gain, not a marketing one.
The AI eTMF Agent strengthens that operating model inside the workflow. It auto-classifies documents, applies metadata tagging, runs QC automation, and maintains a real-time inspection readiness score that updates continuously as documents flow in. Because it acts inside the workflow, it helps resolve routine issues and escalate the rest instead of merely producing another list of exceptions. That is important in validation terms because sponsors can evaluate how automated document classification, metadata application, and QC steps behave within the same controlled environment used to run the trial.
This aligns with ICH E6(R3) Section 4.3 on computerized systems, Section 4.2.2 on relevant metadata and audit trails, and Section 4.2.7 on retention and access. It also supports the practical implementation of 21 CFR Part 11 controls around trusted electronic records and signatures. For sponsors and CROs, the value is not just better documentation. It is a stronger ability to show that the system is still fit for purpose as the trial evolves, because the workflows that matter most to essential records remain visible, connected, and testable.
See how Cloudbyz helps make validation evidence operational across the same CTMS and eTMF environment your teams use to run the trial every day.